Esra Oben Tutar1, Murat Gözüküçük2,3, Münire Sena Kaya4, Ayşenur Macun5, Doğan Yücel5, Sema Hücümenoğlu6, Muzaffer Çaydere6, Yusuf Üstün4. 1. Department of Obstetrics and Gynecology, SBÜ Kırşehir Training and Research Hospital, Kırşehir, Turkey. 2. Department of Obstetrics and Gynecology, SBÜ Ankara Training and Research Hospital, Ankara, Turkey. muratgozukucuk@gmail.com. 3. Sağlık Bakanlığı Ankara Eğitim ve Araştırma Hastanesi, Sakarya Mh. Ulucanlar Cd. No: 89 Altındağ, Ankara, Turkey. muratgozukucuk@gmail.com. 4. Department of Obstetrics and Gynecology, SBÜ Ankara Training and Research Hospital, Ankara, Turkey. 5. Department of Biochemistry, SBÜ Ankara Training and Research Hospital, Ankara, Turkey. 6. Department of Pathology, SBÜ Ankara Training and Research Hospital, Ankara, Turkey.
Abstract
PURPOSE: Ghrelin has previously been proven to have anti-inflammatory and antioxidant properties in preventing cisplatin-induced ovarian damage. The aim of this study was to evaluate the potential effects of this hormone in preventing this damage in rats using histopathological and biochemical methods. METHODS: Twenty-eight Wistar-albino rats were randomly divided into four groups. While no drug was given to Group 1 (sham group), acylated ghrelin was intraperitoneally administered to Group 2 at 0.5 nmol/kg and Group 3 at 2 nmol/kg for 21 days. Group 4 received only saline solution. On the 15th day, a single dose of 5 mg/kg cisplatin was intraperitoneally administered to each rat in Groups 2, 3 and 4. Serum anti-Mullerian hormone (AMH) values were measured on days 0, 15 and 21. Then, laparotomy and bilateral oophorectomy were performed, and the ovaries were histopathologically examined. RESULTS: The number of primordial and primary follicles was significantly higher in Group 3 than in the saline solution + cisplatin group. In Group 4, cisplatin caused significantly higher follicle damage in the primordial, primary and secondary phases compared to the sham group. The AMH level of the SF + cisplatin group was significantly lower than that of the sham group and the high-dose ghrelin + cisplatin group, and the AMH level of the sham group was significantly higher than that of the low-dose ghrelin + cisplatin group. CONCLUSION: High-dose ghrelin was effective in preventing cisplatin-induced ovarian damage by preserving the number of primordial and primary follicles. Larger randomized studies are needed to determine the optimal dosage and duration of ghrelin.
PURPOSE: Ghrelin has previously been proven to have anti-inflammatory and antioxidant properties in preventing cisplatin-induced ovarian damage. The aim of this study was to evaluate the potential effects of this hormone in preventing this damage in rats using histopathological and biochemical methods. METHODS: Twenty-eight Wistar-albino rats were randomly divided into four groups. While no drug was given to Group 1 (sham group), acylated ghrelin was intraperitoneally administered to Group 2 at 0.5 nmol/kg and Group 3 at 2 nmol/kg for 21 days. Group 4 received only saline solution. On the 15th day, a single dose of 5 mg/kg cisplatin was intraperitoneally administered to each rat in Groups 2, 3 and 4. Serum anti-Mullerian hormone (AMH) values were measured on days 0, 15 and 21. Then, laparotomy and bilateral oophorectomy were performed, and the ovaries were histopathologically examined. RESULTS: The number of primordial and primary follicles was significantly higher in Group 3 than in the saline solution + cisplatin group. In Group 4, cisplatin caused significantly higher follicle damage in the primordial, primary and secondary phases compared to the sham group. The AMH level of the SF + cisplatin group was significantly lower than that of the sham group and the high-dose ghrelin + cisplatin group, and the AMH level of the sham group was significantly higher than that of the low-dose ghrelin + cisplatin group. CONCLUSION: High-dose ghrelin was effective in preventing cisplatin-induced ovarian damage by preserving the number of primordial and primary follicles. Larger randomized studies are needed to determine the optimal dosage and duration of ghrelin.
Authors: J Byrne; T R Fears; M H Gail; D Pee; R R Connelly; D F Austin; G F Holmes; F F Holmes; H B Latourette; J W Meigs Journal: Am J Obstet Gynecol Date: 1992-03 Impact factor: 8.661
Authors: F Gaytan; M L Barreiro; L K Chopin; A C Herington; C Morales; L Pinilla; F F Casanueva; E Aguilar; C Diéguez; M Tena-Sempere Journal: J Clin Endocrinol Metab Date: 2003-02 Impact factor: 5.958
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Vishwa Deep Dixit; Eric M Schaffer; Robert S Pyle; Gary D Collins; Senthil K Sakthivel; Ravichandran Palaniappan; James W Lillard; Dennis D Taub Journal: J Clin Invest Date: 2004-07 Impact factor: 14.808